Advanced search×

Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF.

Lancet 335(8687):434-7 (1990) PMID 1968169

In 4 out of 16 patients receiving recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) in phase I/II studies antibodies developed to the recombinant protein. The antibodies react with sites on the native protein backbone which are normally protected by O-linked glycosylation but which are exposed in rhGM-CSF produced in yeast and Escherichia coli. Antigenicity of recombinant human proteins due to non glycosylation may have relevance to the choice of host system for production of factors for clinical use.

Version: za2963e q8za4 q8zb2 q8zcf q8zd7 q8zef q8zfd q8zg3

Similar articles you may find interesting…

  1. Modelling and PBPK simulation in drug discovery.

    AAPS J 11(1):155-66 (2009) PMID 19280352

    Physiologically based pharmacokinetic (PBPK) models are composed of a series of differential equations and have been implemented in a number of commercial software packages. These models require species-specific and compound-specific input parameters and allow for the prediction of plasma and tissue...
  2. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.

    J Clin Pharmacol 49(5):513-33 (2009) PMID 19299532

    Quantitative prediction of human pharmacokinetics is critical in assessing the viability of drug candidates and in determining first-in-human dosing. Numerous prediction methodologies, incorporating both in vitro and preclinical in vivo data, have been developed in recent years, each with advantages...
  3. An Aerial-Hawking Bat Uses Stealth Echolocation to Counter Moth Hearing

    Curr Biol 20(17):1 (2010)